To identify novel hematologic tumor-specific differentially methylated regions, we performed DNA methylation analysis of 7 new candidate genes (ZAR1, GATA4, CDH22, SOX3, SLC16A5, EHD3 and TBPL1), which has been identified to be aberrantly methylated in human cancers or animal models of human cancer. Bone marrow or peripheral blood samples from 20 patients with leukemia (including 10 AML and 6 ALL) before treatment and normal lymphocyte cells from 4 healthy individuals as well as eight human leukemia/lymphoma cell lines were used in this study and analyzed with quantitative DNA methylation analysis using the Sequenom MassARRAY system. All four normal control samples showed no or very low level of cytosine methylation in all of the genomic regions examined. However, leukemia/lymphoma cell lines showed frequent hypermethylation of the ZAR1, SLC16A5, EDH3, GATA4, CDH22 and SOX3 genes. DNA hypermethylation of SOX3 was also frequently observed in most of hematologic malignancy cases. Aberrant hypermethylation of ZAR1, GATA4 and CDH22 was also frequently observed in both Philadelphia chromosome positive and negative ALL samples but not in all 10 AML cases. We identified novel genomic regions of ZAR1, GATA4, CDH22 and SOX3 with aberrant cytosine methylation in hematological malignancies. Among those, aberrant DNA methylation of ZAR1, GATA4 and CDH22 may be involved in carcinogenesis of lymphoid populations.
Introduction
DNA cytosine methylation in CpG dinucleotides is an important epigenetic mechanism and directly involved in the modulation of transcriptional activity and other genome functions. The methylation in CpG-rich promoter regions generally results in transcriptional repression, whereas demethylation plays important roles in transcriptional activation through interaction of transcription factors and/or chromatin-associated protein families. Frequent mutations affecting epigenetic regulators of histone methyltransferases including EZH2 and MLL2, histone demethylases such as UTX and JMJD2C and histone acethyltransferases including CBP and p300 were identified in hematologic malignancies 1) . Not only genetic mutation but also epigenetic perturbations including aberrant DNA methylation have been described during carcinogenesis of hematopoietic cells 2) . Thus, both mutations of epigenetic pathway and perturbation of epigenomic state may play important roles in hematologic malignancies.
Aberrant methylation of specific genes, such as BCL6, CEBPA, PRC2 genes, tumor suppressors of CDKN2B, HOXD8, MLF1 and PCDH8 has been described in hematological malignancy 3, 4) . The development of the technique for genome-wide DNA methylation analysis has allowed us to find perturbed epigenetic patterns including many aberrantly methylated regions in leukemia/ lymphoma, and the reports indicated that some of these aberrantly DNA methylated regions could provide independent predictive value of companion biomarkers for therapeutics, prognostics and survival 5, 6) . Those genomewide surveys of aberrantly methylated genes in leukemia may, however, miss some candidate genes, because of technical pitfalls of the genome wide surveys.
In this report, in order to identify new aberrantly , Hiroki Nagase methylated regions in human leukemia/lymphoma, which may have yet to be identified, and to find surrogate endpoint biomarkers for leukemia/lymphoma, we initially selected 7 candidate genomic regions, which were found to be aberrantly methylated regions in the other type of human cancers and animal models of human cancers and have never been reported to be aberrantly methylated in human leukemia. Then we examined DNA samples from hematologic malignancies by a quantitative methylation analysis using base-specific cleavage and mass spectrometry.
Identification of novel genomic regions with aberrant cytosine methylation in hematological malignancies

Materials and methods
Sample preparation of human hematologic malignancies
Bone marrow samples from 20 patients with leukemia before treatment were obtained from the Laboratory of Hematology and Rheumatology, Nihon University Itabashi Hospital (Tokyo, Japan). Clinical information of each patient is described in Table 1 . Samples were obtained from bone marrow aspiration or peripheral blood and lymphocyte was separated from plasma of the patients using Lympho Separation Medium. Percent of blastic cells was indicated in supplemental table 1. Normal lymphocyte cells from four healthy individuals were used as normal controls. A written informed consent was obtained from all patients involved in the study. The study was approved by the Institutional Review Board of Nihon University Itabashi Hospital and Nihon University School of Medicine. DNA was extracted from cell lines and human tumor specimens by the standard phenol/chloroform purification method or with QIAamp DNAMini Kit (Qiagen, Valencia, CA). 1µg DNAs were extracted from each samples and applied for the methylation analysis.
Selection of candidate aberrant methylated regions
We have preliminary surveyed tissue specific and developmental specific differentially methylated regions (DMRs) in the mouse genome 7) as well as tissue specific DMRs in the human 8) . In addition, previous studies have been searched for aberrant methylation in mouse models of human tumor 9, 10) , the other animal models 11) and the other types of human tumors [12] [13] [14] [15] . The search allows us to find candidate aberrantly methylated regions, where differential methylation was identified both in normal tissue development and in some kind of tumors. Among those regions, 58 loci were identified as differentially methylated region in animal models 16) . Among them, we selected 7 candidate genes (Table 2) , whose CpG island structure were conserved between human and mouse and aberrant methylations have not been identified in human hematopoietic malignancies.
Quantitative analysis of DNA methylation
Bisulfite modification was performed by the sodium bisulfite method with an EZ DNA Methylation-Gold Kit (Zymo Research). The bisulfite-treated genomic DNA was amplified by HotStarTaq DNA Polymerase (Qiagen) (15 min at 94℃ followed by 45 cycles of 20 s at 94℃ , 30 s at 56℃ , and 1 min at 72℃ with a 3-min final extension at 72℃) with specific PCR primers (Operon Biotechnology).
A Sequenom MassARRAY quantitative methylation analysis using the MassARRAY Compact System (Sequenom) was performed for the quantitative DNA methylation analysis. This system is based on MS for the detection and quantitative analysis of DNA methylation using homogeneous Mass Cleave (hMC), base-specific cleavage and MALDI-TOF MS 17) . Briefly, genomic DNA (1 mg) was converted with sodium bisulfite using the EZ DNA methylation-Gold kit (Zymo Research). The primers were designed using Methprimer (http:// www.urogene.org/methprimer/index1.html) or Methyl Primer Express1 Software v1.0 (Applied Biosystems).
The primer pairs were designed to span the conserved human genomic region as indicated. Bisulfite-treated DNA (up to 20 ng/ml) was amplified using HotStarTaq DNA Polymerase (Qiagen) in a 5 ml reaction volume using PCR primers at a 200 nM final concentration (See Table 2 for primer information). The PCR products were checked by agarose gel electrophoresis. After Shrimp Alkaline Phosphatase treatment, 2 ml of the PCR products were used as a template
The non-applicable reading and its corresponding site were eliminated in calculation.
Results
All four normal leukocytes showed less than 25% methylation level within all examined regions, suggesting demethylation of normal leukocyte DNAs at the candidate genes, while 6 out of 7 candidate regions showed frequent hypermethylation in 8 examined lymphoma/ leukemia cell lines (Table 3 and Supplemental Figure  1a) . By the analysis of DNA methylation status of the 7 genes in 20 samples from hematopoietic malignancy patients, hyper-methylation of SOX3 was prominent both in AML and ALL. Six out of 10 AML, all 6 ALL samples showed 50% or higher methylation level at SOX3 locus. Hyper-methylation of ZAR1, GATA4 and CDH22 were observed in ALL samples. All of 6 ALL showed 50% or higher methylation level at ZAR1 locus. Five at GATA4 and 3 at CDH22 were also hyper-methylated. No AML samples reached 50% or higher methylation level at ZAR1, GATA4 and CDH22. Aberrant methylation was not observed at SLC16A5, EHD3 and TBPL1 in any patients' samples examined.
Discussion
This study presents new genes showing aberrant hyper-methylation in the human leukemia genome. A large number of aberrantly methylated regions in hematopoietic malignancies have been reported within or close to the gene. At the present time, DNA hypomethylating agents, such as 5-azacitidine and 5-aza-2'-deoxycitidine, Primers used for MassARRAY EpiTYPER Primers used for PCR amplification of the bisulfite-converted DNA. Each reverse primer has a T7-promotor tag for in vitro transcription (5'-cagtaatacgactcacta tagggagaaggct-3') and the forward primer is tagged with a 10mer to balance Tm (5'-aggaagagag-3'). The average methylation levels of the entire target regions are shown. Genes methylated more than 50% are indicated by gray color. Genome location of each region is shown according to UCSC genome browser, Feb2009 GRCh37/hg19.
Supplemental Figure 1 . have been used for patients with myelodysplastic syndrome (MDS). The use of these drugs results in DNA hypomethylation and gene re-expression, both in vivo and in vitro. Because hypermethylation of the promoters of certain tumor suppressor genes is prevalent in MDS and AML, it is postulated that the DNA hypomethylation induced by DNA demethylating agents may result in the reactivation of silenced genes, restoring their cancer suppressing functions, and inducing cellular differentiation 18) . However, most studies have failed to show a relationship between induction of DNA hypomethylation and clinical response. Those facts indicate that there still exist critical unknown genes epigenetically modified in hematological malignancies. This is the first report to show aberrant methylation of the SOX3 gene in leukemia/lymphoma samples. SOX3 belongs to SOX gene family, encoding transcription factors that act as key regulators of tissue differentiation in embryogenesis. SOXB1 subgroup genes including SOX1, 2 and 3 are widely expressed in neural cells, involved in neural development and differentiation 19) . Dysfunction of SOX3 protein results in failure of cognitive and pituitary development, leading to mental retardation and growth hormone deficiency in human. Little is known about the involvement of SOX3 in tumorigenesis. Presence of antibodies for SOX3 and the other member of SOXB1 family proteins in the serum of small-cell lung cancer (SCLC) patients have been reported, but the role of SOX3 in SCLC development is still unclear 20) . It is interesting that the hyper-methylation of SOX3 was observed both in AML and ALL samples, even though two malignant cells develop after the differentiation from hematopoietic stem cell. The result indicates that the aberrant methylation appears in early hematopoietic lineages before those two distinct commitments. In addition this aberrant methylation could be common event to induce malignancy in both AML and ALL.
In the present study, different DNA methylation patterns were observed in ZAR1, GATA4, and CDH22 between AML and ALL samples. Preferential aberrant hypermethylation was observed in ALL rather than AML, although aberrant DNA methylation is a dominant mechanism in MDS progression to AML and abundant in MDS and secondary AML 21, 22) . Ji H et al. showed that myelopoiesis and lymphopoiesis result in different terminal DNA methylation patterns and, that myeloid commitment is characterized by less global DNA methylation than lymphoid commitment 23) . Gaudet F, et al. demonstrated not only that constitutive DNA methylation was required in the establishment and maintenance of the hematopoietic stem cell (HSC) self-renewal program, but they showed also hypomethylated HSCs intrinsically lack lymphoid developmental potential, whereas they maintain normal myeloid and megakaryoerythroid potential 24) . Although the mechanism of stem cell differentiation and development of leukemic cell (or probable leukemic stem cell) could be different, some DNA methylation pattern might be associated with leukemiagenesis and its differentiation to myeloid or lymphoid populations. Aberrant DNA methylation of ZAR1, GATA4, and CDH22 may be associated with differentiation to lymphoid populations of leukemic stem cell. ZAR1 and GATA4 are known to be involved in fetal development. For instance, ZAR1 is engaged in oocyteembryo transition, and GATA4 is expressed in yolk sac and associated with heart formation. However, little is known about its role in hematological malignancies. Hyper-methylation of the ZAR1 genes in human melanomas and brain tumors were reported recently. Shinojima et al. noted a very high frequency of hypermethylation of the ZAR1 intergenic region in human melanomas, in contrast to non-methylation in both normal human epidermal melanocyte cell lines and melanocytic nevus surgical specimens 9) . Watanabe et al. reported that hypermethylation of ZAR1 in various types of human brain tumors 25) . Seven candidate aberrantly methylated genomic regions, which have yet to be identified by whole genome scan, were analyzed in this study. In four out of seven candidate genes aberrantly methylated in leukemia have been identified. This high frequent detection could be because we screened candidate genes based on the evidence obtained from previous studies in both human and animal model of human cancers. Even though there are some limitations in the study using animal models, there are several advantages, as they have a uniform genetic background, could be kept in a controlled environment, and prone to develop tumors of the same etiology. Those merits let us find out new human candidate genes, which have not been found by the whole genome scan analysis and may be a surrogate marker for clinical endpoints. Since our present data clearly showed that the candidate loci found in the analysis of mouse tumor samples were also aberrantly methylated in human leukemia samples, we are planning to explore more genomic region in DNA methylation and gene expression based on the analysis of mouse tumor samples. Further comparative genomic analysis may elucidate a critical unknown gene epigenetically modified in hematological malignancies.
